Shiseido Co. Ltd, Quality Assessment Centre, Yokohama, Kanagawa, Japan.
Altern Lab Anim. 2010 Aug;38(4):275-84. doi: 10.1177/026119291003800403.
We previously developed the human cell-line activation test (h-CLAT) in vitro skin sensitisation test, based on our reported finding that a 24-hour exposure of THP-1 cells (a human monocytic leukaemia cell line) to sensitisers is sufficient to induce the augmented expression of CD86 and CD54. The aim of this study is to confirm the predictive value of h-CLAT for skin sensitisation activity by employing a larger number of test chemicals. One hundred chemicals were selected, according to their categorisation in the local lymph node assay (LLNA), as being: extreme, strong, moderate and weak sensitisers, and non-sensitisers. The correlation of the h-CLAT results with the LLNA results was 84%. There were some false negatives (e.g. benzoyl peroxide, hexyl cinnamic aldehyde) and some false positives (e.g. 1-bromobutane, diethylphthalate). Eight out of the 9 false negatives (89%) were water-insoluble chemicals. The h-CLAT could positively predict not only extreme and strong sensitisers, but also moderate and weak sensitisers, though the detection rates of weak sensitisers and non-sensitisers were comparatively low. Some sensitisers enhanced both CD86 and CD54 levels, and some enhanced the level of only one of them. The use of the combination of CD86 and CD54 induction as a positive indicator, improved the accuracy of the test. In conclusion, the h-CLAT is expected to be a useful cell-based in vitro method for predicting skin sensitisation potential.
我们之前开发了一种基于人单核白血病细胞系(THP-1 细胞)的体外皮肤致敏试验(h-CLAT),该试验基于我们的发现,即 24 小时暴露于致敏剂足以诱导 CD86 和 CD54 的增强表达。本研究的目的是通过使用更多的测试化学品来确认 h-CLAT 对皮肤致敏活性的预测价值。根据它们在局部淋巴结试验(LLNA)中的分类,选择了 100 种化学品,分别为:极度、强、中、弱致敏剂和非致敏剂。h-CLAT 结果与 LLNA 结果的相关性为 84%。存在一些假阴性(例如过氧化苯甲酰、己基肉桂醛)和一些假阳性(例如 1-溴丁烷、邻苯二甲酸二乙酯)。9 个假阴性中有 8 个(89%)是水不溶性化学品。h-CLAT 不仅可以预测极度和强致敏剂,还可以预测中、弱致敏剂,尽管弱致敏剂和非致敏剂的检出率相对较低。一些致敏剂同时增强了 CD86 和 CD54 水平,而一些致敏剂仅增强了其中一种水平。使用 CD86 和 CD54 诱导的组合作为阳性指标,提高了测试的准确性。总之,h-CLAT 有望成为一种有用的基于细胞的体外方法,用于预测皮肤致敏潜力。